MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

UNC2025 hydrochloride

CAS No. : 2070015-17-5

MCE 国际站：UNC2025 hydrochloride

产品活性：UNC2025 hydrochloride 是一种强效、ATP 竞争性，高口服活性的 Mer/Flt3 抑制剂，IC₅₀ 值分别为 0.74 nM 和 0.8 nM。UNC2025 hydrochloride 对 MERTK 的选择性是 Axl 的 45 倍(IC₅₀=122nM; K_i=13.3 nM)。UNC2025 hydrochloride 具有良好的 PK 特性，可用于急性白血病的研究。

研究领域：Protein Tyrosine Kinase/RTK

作用靶点：FLT3

In Vitro: UNC2025 is against FLT3, MER, AXL, TRKA, TRKC, QIK, TYRO3, SLK, NuaK1, KIT and Met with IC₅₀ values of 0.35 nM, 0.46 nM, 1.65 nM, 1.67 nM, 4.38 nM, 5.75 nM, 5.83 nM, 6.14 nM, 7.97 nM , 8.18 nM and 364 nM, respectively.
UNC2025 (0-60 nM; 1 hour) mediates potent inhibition of Mer phosphorylation with an IC₅₀ of 2.7 nM in 697 B-ALL cells.
UNC2025 (0-60 nM; 1 hour) results in decreased phosphorylation of Flt3 with an IC₅₀ of 14 nM in Flt3-ITD positive Molm-14 acute myeloid leukemia cells.
UNC2025 (3 nM-3 μM; 1 hour) decreases p-MEK, p-AXL, p-TYRO3 expression as a concentration manner in 32D Cells.
UNC2025 (14 nM–10 μM; 48 hours) inhibits MERTK signaling and colony-forming potential in a MERTK-expressing patient sample with a 20-fold difference in sensitivity of MERTK-expressing leukemia blasts relative to normal cord or marrow blood mononuclear cells.
UNC2025 (25-300 nM; 1 hour) mediates potent and dose-dependent decreases in MERTK phosphorylation/activation in both cell lines and inhibition of MERTK correlated with decreased phosphorylation of previously reported MERTK-dependent signaling components STAT6, AKT, and ERK1/2.

In Vivo: UNC2025 (intravenous injection or oral adminstration; 3 mg/kg) exhibits an excellent PK properties: low clearance (9.2 mL/min kg), longer half-life (3.8 h), and high oral exposure (100%), it shows T_max, C_max, and AUClast 0.50 hour, 1.6 μM, and 9.2 h μM, respectively.
UNC2025 (orally adminstration; 50 or 75 mg/kg; 34 and 70 days) mediates a statistically significant dose-dependent reduction in tumor burden relative to vehicle. mediates dose-dependent increases in median survival from 26 days after initiation of treatment in vehicle-treated mice, to 34 and 70 days in mice treated with 50 or 75 mg/kg UNC2025, respectively.

相关产品：Bioactive Compound Library Plus  |  Kinase Inhibitor Library  |  Protein Tyrosine Kinase Compound Library  |  Anti-Cancer Compound Library  |  Orally Active Compound Library  |  Anti-Blood Cancer Compound Library  |  Anti-Prostate Cancer Compound Library  |  Heterocyclic Compound Library  |  Membrane Protein-targeted Compound Library  |  Cytokine Inhibitors Library  |  JNJ-47117096 hydrochloride  |  Sorafenib-d₄  |  AT9283  |  (E/Z)-Zotiraciclib  |  AKN-028 acetate  |  Sorafenib Tosylate  |  BPR1K871  |  ENMD-2076 Tartrate  |  AZD2932  |  Hypothemycin  |  Tandutinib  |  UNC4203  |  3-Hydroxy Midostaurin  |  Cabozantinib  |  LBW242  |  MAX-40279 hemifumarate  |  JAK2-IN-7  |  TAK-659 hydrochloride  |  Gilteritinib-d₈  |  BSc5371  |  FLT3/CDK4-IN-1  |  Tyrphostin AG1296  |  FLT3-IN-4  |  FLT3-IN-18  |  Cabozantinib-d₄  |  Gilteritinib hemifumarate  |  Tuspetinib

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。